Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: Benefit due to influenza and pneumococcal vaccination not demonstrated

Susan A. Skull; Ross M. Andrews; Graham B. Byrnes; Heath A. Kelly; Terence M. Nolan; Graham V. Brown; Donald A. Campbell

doi:10.1016/j.vaccine.2007.03.015

Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: Benefit due to influenza and pneumococcal vaccination not demonstrated

Susan A. Skull, Ross M. Andrews, Graham B. Byrnes, Heath A. Kelly, Terence M. Nolan, Graham V. Brown, Donald A. Campbell

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly ≥65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95%CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95%CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting.

Original language	English
Pages (from-to)	4631-4640
Number of pages	10
Journal	Vaccine
Volume	25
Issue number	23
DOIs	https://doi.org/10.1016/j.vaccine.2007.03.015
Publication status	Published - 6 Jun 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2007.03.015

Cite this

@article{5cfa10753d204110b16ead49abd8c799,

title = "Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: Benefit due to influenza and pneumococcal vaccination not demonstrated",

abstract = "Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly ≥65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95%CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95%CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting.",

keywords = "Influenza vaccines, Pneumococcal vaccines, Pneumonia",

author = "Skull, {Susan A.} and Andrews, {Ross M.} and Byrnes, {Graham B.} and Kelly, {Heath A.} and Nolan, {Terence M.} and Brown, {Graham V.} and Campbell, {Donald A.}",

year = "2007",

month = jun,

day = "6",

doi = "10.1016/j.vaccine.2007.03.015",

language = "English",

volume = "25",

pages = "4631--4640",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "23",

}

TY - JOUR

T1 - Prevention of community-acquired pneumonia among a cohort of hospitalized elderly

T2 - Benefit due to influenza and pneumococcal vaccination not demonstrated

AU - Skull, Susan A.

AU - Andrews, Ross M.

AU - Byrnes, Graham B.

AU - Kelly, Heath A.

AU - Nolan, Terence M.

AU - Brown, Graham V.

AU - Campbell, Donald A.

PY - 2007/6/6

Y1 - 2007/6/6

N2 - Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly ≥65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95%CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95%CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting.

AB - Benefits from influenza and 23-valent pneumococcal polysaccharide (23vPPV) vaccines against invasive pneumococcal disease and laboratory confirmed influenza have been well documented. However, their effectiveness against pneumonia remains controversial for community-based elderly ≥65 years. Using a case-cohort design we examined incremental VE of 23vPPV over and above influenza vaccine against hospitalization with community-acquired pneumonia (HCAP) in two large Australian hospitals. 1952 cases (ICD-10-AM codes for pneumonia: J10-J18) and 2927 randomly selected cohort subjects were studied. Vaccination status was confirmed by providers. Benefit against HCAP was not demonstrated in multivariate analysis for influenza vaccine compared with neither vaccine (RR 1.02, 95%CI 0.84-1.20) or for both vaccines compared with influenza vaccine (RR 0.98, 95%CI 0.81-1.18). The current program of funding these vaccines for the elderly is not having a discernable impact on HCAP in this setting.

KW - Influenza vaccines

KW - Pneumococcal vaccines

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=34248382167&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.03.015

DO - 10.1016/j.vaccine.2007.03.015

M3 - Article

C2 - 17478015

AN - SCOPUS:34248382167

SN - 0264-410X

VL - 25

SP - 4631

EP - 4640

JO - Vaccine

JF - Vaccine

IS - 23

ER -

Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: Benefit due to influenza and pneumococcal vaccination not demonstrated

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this